Abstract
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (including del[17p] and mutations) and/or unmutated IGHV (IGHV-U) have inferior survival to standard first-line chemoimmunotherapies and should be considered for novel agents, such as ibrutinib. This study aims to evaluate the cost-effectiveness of predictive biomarker testing for first-line treatment in patients with CLL from an Australian healthcare system perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
